针对宿主细胞靶位抗HCV策略研究进展
慢性感染;丙型肝炎病毒;宿主细胞因素;治疗,梁雪松,安艳,通讯作者:,Progressintheanti-hepatitisCvirusstrategiestargetingonhostcells,Xue-SongLiang,YanAn,Co
第1页 |
参见附件(852KB,5页)。
梁雪松, 中国人民解放军第二军医大学长海医院感染科 上海市 200433
安艳, 山东省医学科学院放射医学研究所 山东省济南市 250062
通讯作者: 安艳, 250062, 山东省济南市, 山东省医学科学院放射医学研究所. anyan929@sohu.com
收稿日期: 2007-04-01 接受日期: 2007-04-13
Progress in the anti-hepatitis C virus strategies targeting on host cells
Xue-Song Liang, Yan An
Xue-Song Liang,Department of Infectious Diseases, Changhai Hospital Affiliated to the Second Military Medical University, Shanghai 200433, China
Yan An,Institute of Radiation Medicine, Shangdong Academy of Medical Sciences, Ji’nan 250062, Shandong Province, China
Correspondence to:Yan An, Institute of Radiation Medicine, Shangdong Academy of Medical Sciences, Ji’nan 250062, Shandong Province, China. anyan929@sohu.com
Received:2007-04-01 Accepted:2007-04-13
Abstract
Chronic hepatitis C virus (HCV) infection is one of the serious diseases endangered people’s health. The current therapy for HCV infection has limited efficacy, and new and more effective therapies are pressingly needed. Host cell factors that are required for HCV infection, replication and/or pathogenesis represent potential therapeutic targets. The most interesting cellular factors are cellular receptors that mediate HCV entry, factors that facilitate HCV replication and assembly, and intracellular pathways involving lipid biosynthesis, oxidative stress and innate immune response. The key issue now is to manipulate such cellular targets pharmacologically for the treatment of chronic HCV infection, without being limited by side effects. This paper mainly related to the nearest years of research progress for a brief overview.
Key Words: Chronic infection; Hepatitis C virus; Cellular factors; Therapy
Liang XS, An Y. Progress in the anti-hepatitis C virus strategies targeting on host cells. Shijie Huaren Xiaohua Zazhi 2007;15(15):1754-1758
摘要
慢性HCV(CHC)感染是严重危害人类健康疾病之一. 现阶段HCV治疗策略疗效有限, 有必要寻找更新更好的抗HCV策略 ......
您现在查看是摘要介绍页,详见PDF附件(852KB,5页)。